Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.
Zampelas
Antonis
A
Agricultural University of Athens, Department of Food Science and Technology, Unit of Human Nutrition, Lera Odos 75, 11855 Athens, Greece. azampelas@aua.gr
D000284:Administration, Oral; D002214:Capsules; D002340:Carotid Artery Diseases / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000601:surgery; D019587:Dietary Supplements; D004281:Docosahexaenoic Acids / Q000008:administration & dosage* / Q000097:blood; D004338:Drug Combinations; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism; D016894:Endarterectomy, Carotid; D005487:Foam Cells / Q000187:drug effects / Q000276:immunology; D005786:Gene Expression Regulation; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000601:surgery; D018836:Inflammation Mediators / Q000032:analysis; D020782:Matrix Metalloproteinases / Q000235:genetics; D010743:Phospholipids / Q000378:metabolism; D011300:Preoperative Care; D012422:Rupture, Spontaneous; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
D002214:Capsules; D004338:Drug Combinations; D018836:Inflammation Mediators; D010743:Phospholipids; D004281:Docosahexaenoic Acids; C035276:eicosapentaenoic acid ethyl ester; D015118:Eicosapentaenoic Acid; C405603:Omacor; D020782:Matrix Metalloproteinases